Today: 9 June 2026
Browse Category

NASDAQ:VRSN 29 November 2025 - 25 April 2026

VeriSign Falls After Q1 Beat as .Com Price Hike Puts Renewal Risk in Focus

VeriSign Falls After Q1 Beat as .Com Price Hike Puts Renewal Risk in Focus

VeriSign reported first-quarter revenue of $429 million, up 6.6%, and net income of $215 million, as .com and .net registrations rose to 176.1 million. Shares fell 2.8% Friday to $269.20 after the company announced a Nov. 1 increase in the wholesale .com fee to $10.97. Management raised its 2026 growth outlook for domain registrations. Investors remain cautious over renewal and pricing risks.
25 April 2026
··
VeriSign stock dives nearly 10% after outlook, costs take the shine off results

VeriSign stock dives nearly 10% after outlook, costs take the shine off results

VeriSign shares dropped nearly 10% Friday after its quarterly report, underperforming a rising market. The company raised its dividend and maintained heavy buybacks, but 2026 guidance and .com pricing limits drew scrutiny. Fourth-quarter revenue reached $425 million with net income of $206 million. Post-hearing briefs in the .web arbitration are expected in the first half of 2026.
6 February 2026
··
VeriSign (VRSN) Stock Outlook Before the December 1, 2025 Open: Price, Latest News and Analyst Forecasts

VeriSign (VRSN) Stock Outlook Before the December 1, 2025 Open: Price, Latest News and Analyst Forecasts

VeriSign (NASDAQ: VRSN) closed at $251.99 after a Black Friday session with trading volume near 1.8 million shares, well above recent averages. The stock remains about 18–20% below its July peak but is up roughly 23% year-to-date. Institutional ownership stands near 93%, with recent filings showing continued repositioning and insider selling. No major pre-market price moves indicated ahead of the December 1 open.
1 December 2025
·
VeriSign (VRSN) Stock on November 29, 2025: Volume Spike, JPMorgan Selling and Buffett Overhang – What Investors Need to Know

VeriSign (VRSN) Stock on November 29, 2025: Volume Spike, JPMorgan Selling and Buffett Overhang – What Investors Need to Know

VeriSign shares saw trading volume nearly double to 1.85 million on November 29, 2025, after new filings showed JPMorgan Chase trimmed its stake. The activity follows Berkshire Hathaway’s $1.23 billion sale of one-third of its holdings this summer. Shares closed at $251.99, down 0.27%, with the stock about 20% below its 52-week high. Q3 revenue rose 7.3% to $419.1 million, with diluted EPS at $2.27.
29 November 2025
·

Stock Market Today

  • Wheat Prices Mixed as Winter Wheat Gains on U.S. Crop Progress
    June 9, 2026, 9:22 AM EDT. Wheat markets closed mixed on Monday, with winter wheat futures rising across Chicago and Kansas City exchanges, while Minneapolis spring wheat fell slightly. The U.S. Department of Agriculture's Crop Progress report showed 92% of winter wheat heading, 7% ahead of average, and spring wheat planting at 98%, with improving crop conditions. Export inspections dropped 20.65% from last week but marketing year shipments rose 9.13% compared to last year. Ukraine's wheat crop estimate increased by 1.8 million tonnes to 21.7 million tonnes. Futures finished with Chicago SRW wheat up 1 to 3 ¼ cents and Kansas City HRW wheat up 2 ¼ to 9 cents, contrasting the modest decline in Minneapolis spring wheat.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Go toTop